REDUCTION OF THE RISK OF GLAUCOMATOUS OPTIC NEUROPATHY PROGRESSION AFTER COMPLEX NEUROPROTECTION
DOI:
https://doi.org/10.32782/2226-2008-2025-2-5Keywords:
glaucomatous optic neuropathy, neuroprotection, photobiomodulation, nutraceutical, resveratrolAbstract
The problem of glaucomatous neurodegeneration with progressive death of retinal ganglion cells (RGCs) and development of visual field defects can lead to irreversible blindness. In this regard, there is a need to search for effective strategies for neuroprotection of RGCs.Objective. To study the risk of glaucomatous optic neuropathy (GON) progression in patients with primary open-angle glaucoma (POAG) after complex neuroprotection by photobiomodulation (PBM) and nutraceutical formula AREDS2 with ω-3 polyunsaturated fatty acids (PUFA) enhancement and resveratrol for a 12- month follow-up.Material and methods. A total of 137 patients (137 eyes) diagnosed with early or advanced POAG were examined. The main group (group 1) included 74 patients, the control group (group 2) – 63 patients. All patients underwent PBM therapy. Patients of group 1 were additionally recommended the nutraceutical formula AREDS2, enriched with ω-3 PUFA and resveratrol 60 mg (Resvega® Forte; Théa, France; 2 capsules per day) for 12 months. Using Cox regression, the relative risk (cumulative risk function) for predicting the progression of GON was calculated.Results. After 12 months of observation, the median POAG in group 1 exceeded the initial level by 15%. Stabilization and a tendency to improve the parameters of retinal morphometry, Humphrey computer perimetry, as well as an improvement in intraocular blood volume by 24% (p = 0.001) were noted. In the control group, deterioration in all parameters was noted.Conclusions. Complex neuroprotection using PBM and taking the AREDS2 nutraceutical with ω-3 PUFA and resveratrol (60 mg) for 12 months in patients with POAG can reduce the relative risk of progression of GON by 2.27 times (95% DI 1, 38–3.75).
References
Baik JS, Lee TY, Kim NG, et al. Effects of Photobiomodulation on Changes in Cognitive Function and Regional Cerebral Blood Flow in Patients with Mild Cognitive Impairment: A Pilot Uncontrolled Trial. J Alzheimers Dis. 2021; 83(4): 1513–1519. DOI: 10.3233/jad-210386.
Bata AM, Fondi K, Witkowska KJ, et al. Optic nerve head blood flow regulation during changes in arterial blood pressure in patients with primary open-angle glaucoma. Acta Ophthalmol. 2019; 97(1): e36–e41. DOI: 10.1111/aos.13850.
Chao LL. Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia: A Pilot Trial. Photobiomodul Photomed Laser Surg. 2019 Mar; 37(3): 133–141. DOI: 10.1089/photob.2018.4555.
Chronopoulos P, Manicam C, Zadeh JK, et al. Effects of Resveratrol on Vascular Function in Retinal Ischemia-Reperfusion Injury. Antioxidants (Basel). 2023 Apr 1; 12(4): 853. https://doi.org/10.3390/antiox12040853.
European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021; 105 (Suppl 1): 1–169. DOI: 10.1136/bjophthalmol-2021-egsguidelines.
Ghita AM, Iliescu DA, Ghita AC, et al. Ganglion Cell Complex Analysis: Correlations with Retinal Nerve Fiber Layer on Optical Coherence Tomography. Diagnostics (Basel). 2023 Jan 11; 13(2): 266. DOI: 10.3390/diagnostics13020266.
Golmohammadi M, Meibodi SAA, Al-Hawary SIS, et al. Neuroprotective effects of resveratrol on retinal ganglion cells in glaucoma in rats: A narrative review. Animal Model Exp Med. 2024 Jun; 7(3): 195–207. DOI: 10.1002/ame2.12438.
Guzun OV, Khramenko NI, Slobodianyk SB, et al. Efficacy of complex neuroprotection of glaucomatous optic neuropathy [Efficiency of complex neuroprotection in glaucomatous optic neuropathy]. J. Ophthalmol. 2018; 5: 32–38. https://doi.org/10.31288/oftalmolzh201853238.
Hamblin MR. Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation. Photochem Photobiol. 2018; 94(2): 199–212. DOI: 10.1111/php.12864.
Hu HJ, Li P, Tong B, et al. Values of macular ganglion cell-inner plexiform layer and 10-2 visual field measurements in detecting and evaluating glaucoma. Int J Ophthalmol. 2024 May 18; 17(5): 852–860. DOI: 10.18240/ijo.2024.05.09.
Li K, Bathini M, Raghushaker CR, Mahato KK. The Molecular Mechanisms of Action of Photobiomodulation Against Neurodegenerative Diseases: A Systematic Review. Cell Mol Neurobiol. 2022 May; 42(4): 955–971. DOI: 10.1007/ s10571-020-01016-9.
Osborne NN, Núñez-Álvarez C, Joglar B, et al. Glaucoma: Focus on mitochondria in relation to pathogenesis and neuroprotection. Eur J Pharmacol. 2016 Sep 15; 787: 127–33. DOI: 10.1016/j.ejphar.2016.04.032.
Pang Y, Qin M, Hu P, et al. Resveratrol protects retinal ganglion cells against ischemia induced damage by increasing Opa1 expression. Int J Mol Med. 2020 Nov; 46(5): 1707–1720. DOI: 10.3892/ijmm.2020.4711.
Tezel G. Multifactorial Pathogenic Processes of Retinal Ganglion Cell Degeneration in Glaucoma towards Multi-Target Strategies for Broader Treatment Effects. Cells. 2021 Jun 2; 10(6): 1372. DOI: 10.3390/cells10061372.
Van Eijgen J, Melgarejo JD, Van Laeken J, et al. The Relevance of Arterial Blood Pressure in the Management of Glaucoma Progression: A Systematic Review. Am J Hypertens. 2023 Feb 15; 37(3): 179–198. DOI: 10.1093/ ajh/hpad111.
Wong D, Chua J, Lin E, et al. Focal Structure-Function Relationships in Primary Open-Angle Glaucoma Using OCT and OCT-A Measurements. Invest Ophthalmol Vis Sci. 2020 Dec 1; 61(14): 33. DOI: 10.1167/iovs.61.14.33.
Ye MJ, Meng N. Resveratrol acts via the mitogen-activated protein kinase (MAPK) pathway to protect retinal ganglion cells from apoptosis induced by hydrogen peroxide. Bioengineered. 2021; 12(1): 4878–4886. DOI: 10.1080/21655979.2021.1954742.
Zabel K, Zabel P, Kaluzna M, et al. Correlation of retinal sensitivity in microperimetry with vascular density in optical coherence tomography angiography in primary open-angle glaucoma. PLOS ONE. 2020; 15(7): e0235571. DOI: 10.1371/ journal.pone.0235571.
Zadorozhnyy O, Korol A, Nasinnyk I, et al. Photobiomodulation therapy in ophthalmology. J Ophthalmol (Ukraine). 2022; 5: 47–53. http://doi.org/10.31288/oftalmolzh202254753.
Zhang N, Wang J, Li Y, Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Sci Rep. 2021 Jul 2; 11(1): 13762. DOI: 10.1038/s41598-021-92971-w.
